About Rallybio Company
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.
Where Rallybio Stands With Analysts
Within the last quarter, Rallybio (NASDAQ:RLYB) has observed the following analyst ratings: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings32000Last 30D100001M Ago110002M Ago000
HC Wainwright & Co. Reiterates Buy on Rallybio, Maintains $17 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rallybio (NASDAQ:RLYB) with a Buy and maintains $17 price target.
Analysts Offer Insights on Healthcare Companies: Edesa Biotech (EDSA), Cabaletta Bio (CABA) and Rallybio (RLYB)
In reaction to earnings/guidance:
• $GoodRx(GDRX.US)$ +38.5%,$EDGIO(EGIO.US)$ +13.5%,$Lemonade(LMND.US)$ +10.7%,$Desktop Metal(DM.US)$ +8.5%,$ShockWave Medical(SWAV.US)$ +8.2%,$Pubmatic(PUBM.US)$ +8.1%,$Olaplex(OLPX.US)$ +7%,$Vivid Seats(SEAT.US)$ +6.4%,$Noble(NE.US)$ +6.3%,$Aspen Technology(AZPN.US)$ +5.4%,$AAON Inc(AAON.US)$ +5%,$Hudbay Minerals(HBM.US)$ +5%,$Vivint Smart Home(VVNT.US)$ +4.9%,$Vivint Smart Home(VVNT.US)$ +4...